Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical firm, said on Wednesday that it has signed a Letter of Intent or LoI to merge with Algorithm Sciences, Inc., a company focused on Pulmonary Arterial Hypertension or PAH.
Post transaction, Hoth shareholders are expected to own around 14% of the combined company, whereas Algorithm shareholders are anticipated to own remaining approximately 86%.
Robb Knie, CEO of Hoth, said: "The combination of assets in the combined company translates to additional billions of dollars in market opportunity for current shareholders. Algorithm's executive team along with its science professionals brings a seasoned executive focus on commercialization and monetization of the now robust advanced pipeline…"
Algorithm pipeline focused on PAH, a rare disease with a prevalence of around 100,000 patients in the U.S. The global PAH treatment market size was valued at $7.2 billion in 2021, and is projected to reach $12 billion by 2031.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.